Literature DB >> 2001071

Plasma levels of tumor necrosis factor in the adult respiratory distress syndrome.

R Roten1, M Markert, F Feihl, M D Schaller, M C Tagan, C Perret.   

Abstract

The purpose of the study was to evaluate the role of tumor necrosis factor alpha (TNF alpha) in the pathogenesis of acute lung injury in critically ill patients. An immunoradiometric assay with an upper normal limit of 9 pg/ml was used to measure plasma TNF alpha levels (pl-TNF alpha) in 34 patients with adult respiratory distress syndrome (ARDS) and in 16 patients in whom, despite the presence of risk factors, ARDS did not develop. Pl-TNF alpha was elevated in 76% of the patients with ARDS (71 +/- 104 pg/ml) and in 48% of the at-risk patients (47 +/- 73 pg/ml); the difference between the two groups was not statistically significant. In 13 patients studied serially from the onset (Day 0) to the fifth day of ARDS, the peak pl-TNF alpha occurred later than Day 0 in seven subjects. Although the highest pl-TNF alpha levels were found in septic patients, moderately elevated values were also observed in 56% of nonseptic subjects. We conclude that plasma TNF alpha level is not a marker of ARDS but rather of shock and sepsis. These results do not exclude a pathogenic role of TNF alpha in acute lung injury since this cytokine could be produced and exert its effects within the lungs. The large incidence of abnormally high could be produced and exert its effects within the lungs. The large incidence of abnormally high plasma TNF alpha levels raises important questions on the role of this toxic cytokine in other disorders occurring in critically ill patients.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2001071     DOI: 10.1164/ajrccm/143.3.590

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  16 in total

1.  MV causes lung inflammation and systemic immune depression. A balance of fire and ice.

Authors:  P M Suter
Journal:  Intensive Care Med       Date:  2002-02-09       Impact factor: 17.440

Review 2.  Immunological perspectives in prevention and treatment of nosocomial pneumonia.

Authors:  J E Pennington
Journal:  Intensive Care Med       Date:  1992       Impact factor: 17.440

Review 3.  Trauma and the immune response.

Authors:  R M Smith; P V Giannoudis
Journal:  J R Soc Med       Date:  1998-08       Impact factor: 5.344

Review 4.  Biomarkers in acute lung injury.

Authors:  Maneesh Bhargava; Chris H Wendt
Journal:  Transl Res       Date:  2012-02-07       Impact factor: 7.012

5.  Comparison of systemic cytokine levels in patients with acute respiratory distress syndrome, severe pneumonia, and controls.

Authors:  T T Bauer; C Montón; A Torres; H Cabello; X Fillela; A Maldonado; J M Nicolás; E Zavala
Journal:  Thorax       Date:  2000-01       Impact factor: 9.139

Review 6.  Anti-TNFα therapy in inflammatory lung diseases.

Authors:  Rama Malaviya; Jeffrey D Laskin; Debra L Laskin
Journal:  Pharmacol Ther       Date:  2017-06-19       Impact factor: 12.310

7.  Tumor necrosis factor-alpha-mediated decrease in glutathione increases the sensitivity of pulmonary vascular endothelial cells to H2O2.

Authors:  Y Ishii; C A Partridge; P J Del Vecchio; A B Malik
Journal:  J Clin Invest       Date:  1992-03       Impact factor: 14.808

8.  A critical role for phosphatidylinositol (3,4,5)-trisphosphate-dependent Rac exchanger 1 in endothelial junction disruption and vascular hyperpermeability.

Authors:  Ram P Naikawadi; Ni Cheng; Stephen M Vogel; Feng Qian; Dianqing Wu; Asrar B Malik; Richard D Ye
Journal:  Circ Res       Date:  2012-09-10       Impact factor: 17.367

9.  Phagocyte function and cytokine production in community acquired pneumonia.

Authors:  K Moussa; H J Michie; I A Cree; A C McCafferty; J H Winter; D P Dhillon; S Stephens; R A Brown
Journal:  Thorax       Date:  1994-02       Impact factor: 9.139

Review 10.  A Pathophysiologic Approach to Biomarkers in Acute Respiratory Distress Syndrome.

Authors:  Raiko Blondonnet; Jean-Michel Constantin; Vincent Sapin; Matthieu Jabaudon
Journal:  Dis Markers       Date:  2016-02-11       Impact factor: 3.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.